THIO Sequenced With Cemiplimab in Advanced NSCLC
A phase 2 trial of Cemiplimab in non-small-cell lung cancer, run by Maia Biotechnology, active and no longer recruiting.
Overview
THIO Sequenced With Cemiplimab in Advanced NSCLC is a phase 2 interventional study registered as NCT05208944 by Maia Biotechnology, with 227 participants enrolled, started 2022-06-08 and due to reach its primary completion in 2027-09-30. Interventions recorded: 6-Thio-2'-Deoxyguanosine and Cemiplimab.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Shares Maia Biotechnology, Cemiplimab, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Shares Cemiplimab and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialFirst-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI
Shares Non-small-cell lung cancer and the tag pipeline.